Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 affibody molecules

Bioconjugate Chemistry

Volumn 19, Issue 12, 2008, Pages 2568-2576

  Tran, Thuy A ^a   Ekblad, Torun ^d   Orlova, Anna ^a,e   Sandström, Mattias ^b   Feldwisch, Joachim ^e   Wennborg, Anders ^e   Abrahmsén, Lars ^e   Tolmachev, Vladimir ^a,c,e   Karlström, Amelie Eriksson ^d  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^e Affibody AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; LYSINE; SERINE; TECHNETIUM 99M; THIOGLYCOLIC ACID; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CHELATION; CHEMICAL LABELING; CONTROLLED STUDY; FEMALE; GAMMA SCINTIGRAPHY; GASTROINTESTINAL TRACT; HUMAN; HUMAN CELL; INTERNALIZATION; LIVER; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; RADIOACTIVITY; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; URINARY EXCRETION;

MUS;

EID: 58149083156     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc800244b     Document Type: Article

References (33)

1. Pegram, M. D., Pauletti, G., and Slamon, D. J. (1998) HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat. 52, 65-77.
2. Yarden, Y. (2001) Biology of HER2 and its importance in breast cancer. Oncology 61, 1-13, Suppl 2.
3. Stern, D. F., Heffernan, P. A., and Weinberg, R. A. (1986) p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol. Cell. Biol. 6, 1729-40.
4. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-82.
5. Moy, B., and Goss, P. E. (2006) Lapatinib: current status and future directions in breast cancer. Oncologist 11, 1047-57.
6. Bast, R. C., Jr., Ravdin, P., Hayes, D. F., Bates, S., Fritsche, H., Jr., Jessup, J. M., Kemeny, N., Locker, G. Y., Mennel, R. G., and Somerfield, M. R. (2001) 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 19, 1865-78.
7. Hicks, D. G., and Kulkarni, S. (2008) HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am. J. Clin. Pathol. 129, 263-73.
8. Wolff, A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., McShane, L. M., Paik, S., Pegram, M. D., Perez, E. A., Press, M. F., Rhodes, A., Sturgeon, C., Taube, S. E., Tubbs, R., Vance, G. H., van de Vijver, M., Wheeler, T. M., and Hayes, D. F. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 131, 18.
9. Tolmachev, V. (2008) Imaging of HER-2 overexpression in tumors for guiding therapy. Curr. Pharm. Des. 14, 2999-3019.
10. Tolmachev, V., Orlova, A., Nilsson, F. Y., Feldwisch, J., Wennborg, A., and Abrahmsen, L. (2007) Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin. Biol. Ther. 7, 555-68.
11. Nilsson, F. Y., and Tolmachev, V. (2007) Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr. Opin. Drug Discovery Dev. 10, 167-75.
12. Cai, W., Niu, G., and Chen, X. (2008) Multimodality imaging of the HER-kinase axis in cancer. Eur. J. Nucl. Med. Mol. Imaging 35, 186-208.
13. Nord, K., Gunneriusson, E., Ringdahl, J., Stahl, S., Uhlen, M., and Nygren, P. A. (1997) Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain. Nat. Biotechnol. 15, 772-7.
14. Orlova, A., Magnusson, M., Eriksson, T. L., Nilsson, M., Larsson, B., Hoiden-Guthenberg, I., Widstrom, C., Carlsson, J., Tolmachev, V., Stahl, S., and Nilsson, F. Y. (2006) Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 66, 4339-48.
15. 111In]-benzyl- DOTA-ZHER2:342, a potential agent for imaging of HER2 expression in malignant tumors. Int. J. Mol. Med. 20, 397-404.
16. 111In-benzyl-DTPA- ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J. Nucl. Med. 47, 846-53.
17. 177Lu]- DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. Int. J. Mol. Med. 19, 285-91.
18. 18)F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 35, 1008-18.
19. 18)F]fluorobenzaldehyde via oxime chemistry. Mol. Imaging Biol. 10, 177-81.
20. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody. Eur. J. Nucl. Med. Mol. Imaging 34, 1843-53.
21. 99mTc labeling. Nucl. Med. Biol. 28, 703-8.
22. 99mTc-labelled peptides. Q. J. Nucl. Med. 46, 195-205.
23. HER2:342, an affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjugate Chem. 18, 1956-64.
24. 99mTc- labelled Affibody molecules with reduced renal uptake. Eur. J. Nucl. Med. Mol. Imaging, In press.
25. 177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur. J. Nucl. Med. Mol. Imaging 32, 1457-62.
26. 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur. J. Nucl. Med. Mol. Imaging 34, 722-733.
27. Ahlgren, S., Orlova, A., Rosik, D., Sandstrom, M., Sjoberg, A., Baastrup, B., Widmark, O., Fant, G., Feldwisch, J., and Tolmachev, V. (2008) Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjugate Chem. 19, 235-43.
28. 99mTc to tumor-targeting affibody molecules. Bioconjugate Chem. 18, 549-558.
29. 111/114m)In]CHX-A′-DTPA- Z(HER2:342), an affibody ligand conjugate for targeting of HER2-expressing malignant tumors. Q. J. Nucl. Med. Mol. Imaging 51, 314-23.
30. Schmidt, M. M., Thurber, G. M., and Wittrup, K. D. (2008) Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability, Cancer Immunol. Immunother. PMID:18408925.
31. Nishikawa, M., Hasegawa, S., Yamashita, F., Takakura, Y., and Hashida, M. (2002) Electrical charge on protein regulates its absorption from the rat small intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 282, G711-9.
32. Ma, S. F., Nishikawa, M., Katsumi, H., Yamashita, F., and Hashida, M. (2005) Cationic charge-dependent hepatic delivery of amidated serum albumin. J. Controlled Release 102, 583-94.
33. Foulon, C. F.,Welsh, P. C., Bigner, D. D., and Zalutsky, M. R. (2001) Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR. Nucl. Med. Biol. 28, 769-77.